# Safety, Tolerability, and Pharmacokinetics After a Single Dose of Orally Inhaled DNAzyme Solution for Nebulisation in Male Patients With Asthma

> **NCT01577953** · PHASE1 · COMPLETED · sponsor: **Sterna Biologicals GmbH & Co. KG** · enrollment: 24 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** SB010
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01577953
- **Lead sponsor:** Sterna Biologicals GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01577953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01577953, "Safety, Tolerability, and Pharmacokinetics After a Single Dose of Orally Inhaled DNAzyme Solution for Nebulisation in Male Patients With Asthma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01577953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*